Endologix (NSDQ:ELGX) yesterday spiked its plan to sell as much as $25 million worth of its own stock, saying it has no intention of selling stock over the short term. The Irvine, Calif.-based company had tapped Piper Jaffray to offer more than 22.2 million shares at $6.45 apiece, with the proceeds earmarked for manufacturing, clinical trials, […]
Business/Financial News
Wall Street Beat | Earnings Reports | Funding Roundup | Mergers & Acquisitions | Initial Public Offerings | Legal News
Niowave raises $3m in equity funding
Niowave raised $3 million in equity funding, company CFO Mike Zamiara confirmed after the company filed an SEC Form D this week. Zamiara told MassDevice.com via email that the funding “allows us to continue to develop our medical isotope program,” while it also will help the company meet its match requirement for a grant from […]
Stealthy Provisio Medical adds $2m
Stealthy endovascular device developer Provisio Medical added more than $2 million to its coffers in a new equity round, according to a regulatory filing. San Diego-based Provisio is tight-mouthed about its technology, apart from revealing its focus on endovascular therapy on its single-page website. The equity and preferred stock offering brought in $2.3 million of a […]
Former FDA commissioners want more funding for real-world evidence
Three former FDA commissioners are calling on Congress to fully fund the agency’s $60 million fiscal year 2020 budget for using more real-world evidence to evaluate drugs, biologics and devices. Most of that money — $23 million — is earmarked for medical devices. The document is titled “Expanding the Use of RealWorld Evidence in Regulatory […]
FDA lures Vyaire exec Desai for CTO | Personnel Moves, August 23, 2019
The FDA lured former Vyaire Medical executive Vid Desai to take over as permanent CTO, according to Politico. Desai replaces acting CTO Mohammed Sohail Chaudhry, who’s held the role on an interim basis since 2015. Ebb Therapeutics puts Röösli in the corner office Insomnia device maker Ebb Therapeutics said yesterday that it put Eduard Röösli […]
Essex Woodlands raises $745m for second fund
Private equity shop Essex Woodland yesterday said it raised $745 million for its over-subscribed second EW Healthcare Partners fund. The raise is nearly $100 million more than EW’s $650 million goal and tops its first fund b y some $200 million, the New York City-based firm said. The PE investor said it looks for fast-growing, […]
These 5 DIY medical devices might surprise you
Big ideas in medical device development can come from regular people driven to solve vexing problems. Here are a handful of folks from outside the medtech industry who decided to create devices to solve their own health troubles or those of others around the world. Read on to see what high school, college and medical […]
Ambu dives on spiked distributor deal, lowered outlook
Shares in Danish endoscope maker Ambu (CPH:AMBU-B) took a dive today in Copenhagen after it spiked its deal with a U.S. distributor and slashed its outlook on the rest of the year. The Ballerup, Denmark-based company said it’s planning to cut ties with Tri-anim Health Services on the U.S. sales of its aScope pulmonary endoscopes […]
BioSig raises nearly $3.3 million for new, non-EP company
Cardiac arrhythmia-detection startup BioSig Technologies (NSDQ:BSGM) has raised $3.26 million for a subsidiary that is developing more applications for its electrogram-evaluation technology. The company attributed the funding round to 17 investors, according to a regulatory filing. It began the offering on August 5 with a goal of raising $3.6 million. BioSig formed NeuroClear Technologies in November […]
Edwards Lifesciences slides after FDA slaps Class I on Sapien 3 Ultra recall
Edwards Lifesciences (NYSE:EW) shares slid today after the FDA slapped Class I status on last month’s recall of its Sapien 3 Ultra replacement heart valve. Irvine, Calif.-based Edwards in July warned doctors about the risk of burst balloons during implantation of the transcatheter aortic valve replacement, cautioning physicians to closely follow the instructions for use to […]
Varian closes $90m microspheres buy from Boston Scientific
Hot on the heels of the $4 billion buyout of BTG by Boston Scientific (NYSE:BSX), Varian (NYSE:VAR) said yesterday that it closed the $90 million acquisition of Boston’s microspheres business. The deal for the drug-eluting and “bland” embolic microsphere business, which includes the Oncozene, Embozene and Embozone Tandem products, was struck to mollify anti-trust regulators about the BTG […]